Phaseline

Companies › Galmed Pharmaceuticals

Galmed Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Aramchol
Bile acid analog
–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07251712AramcholPhase 1HealthyOtherApr 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.